ANAPTYSBIO, INC. Earnings Per Share, Basic and Diluted
ANAPTYSBIO, INC. (ANAB) reported Earnings Per Share, Basic and Diluted of -$0.66 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-04
- ANAPTYSBIO, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.66.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.87.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.79.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.30.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for fiscal 2020 was -$0.73.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for fiscal 2019 was -$3.60.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for fiscal 2018 was -$2.50.
- ANAPTYSBIO, INC. earnings per share, basic and diluted for fiscal 2017 was -$1.52.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$0.66 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | -$0.73 10-K · filed 2021-02-25 | |||
| 2020-09-30 | -$0.87 10-Q · filed 2020-11-04 | -$1.96 10-Q · filed 2020-11-04 | ||
| 2020-06-30 | -$0.79 10-Q · filed 2020-08-10 | -$1.09 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | -$0.30 10-Q · filed 2021-05-04 | |||
| 2019-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.89 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$2.78 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$3.60 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.15 10-Q · filed 2020-11-04 | -$2.03 derived: net income ÷ weighted average shares · filed 2020-11-04 | -$2.85 10-Q · filed 2020-11-04 | -$3.49 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2019-06-30 | -$0.89 10-Q · filed 2020-08-10 | -$1.70 10-Q · filed 2020-08-10 | -$2.34 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$3.01 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2019-03-31 | -$0.82 10-Q · filed 2020-05-06 | -$1.45 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$2.12 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$2.70 derived: net income ÷ weighted average shares · filed 2021-02-25 |
| 2018-12-31 | -$0.63 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.29 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$1.87 derived: net income ÷ weighted average shares · filed 2021-02-25 | -$2.50 10-K · filed 2021-02-25 |
| 2018-09-30 | -$0.66 10-Q · filed 2019-11-08 | -$1.23 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.86 10-Q · filed 2019-11-08 | -$2.17 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2018-06-30 | -$0.57 10-Q · filed 2019-08-08 | -$1.20 10-Q · filed 2019-08-08 | -$1.51 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.96 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2018-03-31 | -$0.63 10-Q · filed 2019-05-07 | -$0.94 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.38 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.54 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2017-12-31 | -$0.30 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$0.73 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$0.88 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.52 10-K · filed 2020-03-02 |
| 2017-09-30 | -$0.45 10-Q · filed 2018-11-08 | -$0.58 derived: net income ÷ weighted average shares · filed 2019-02-28 | -$1.24 10-Q · filed 2018-11-08 | |
| 2017-06-30 | -$0.13 10-Q · filed 2018-08-07 | -$0.79 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | -$0.75 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | -$1.62 10-K · filed 2019-02-28 | |||
| 2016-03-31 | -$0.34 10-Q · filed 2017-05-12 | |||
| 2015-12-31 | -$2.12 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |